Esolate Press Release

Esolate would like to congratulate our exclusive Pharmaceutical Cannabinoid Licensee, Avata Biosciences, for their recent announcement in signing a Co-Development and Licensing Agreement with Oceanus Bio for Exclusive Rights in Japan and Asia (Excluding China and India) for Novel Adult and Paediatric Oral Cannabidiol Therapies for Development in Epilepsy and Schizophrenia. 

Avata Biosciences, a pioneering biopharmaceutical company specializing in neuroscience drug discovery and clinical development, today announced it has signed a co-development and licensing agreement with Oceanus Bio, Inc. for the exclusive rights to AVAT-021 and AVAT-022 in Japan and Asia, except in China and India. 

Oceanus Bio, Inc. is a clinical-stage pharmaceutical company founded by Kazunari Tsunaba and built upon proven leadership experience from Novartis Japan and Aculys Japan. With a mission to accelerate access to breakthrough therapies in Asia, Oceanus brings deep CNS expertise and a track record of successful drug development and commercialization in Japan. 

Esolate welcomes this Co-Development and Licensing relationship between Avata and Oceanus. “We look forward to supporting the important work undertaken by Avata and Oceanus to advance patient-friendly, solid dose investigational CBD medicines in Japan and Asia,” Hardin Jackson, Chief Executive Officer of Esolate LTD and Esolate Pharmaceuticals LTD.  

For more information about this development please see the Press Release